Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Must be highly accurate then to feed those conspiracy theories.
I have seen 500K, but never 500,000,000 on the ask or 100,000,000. The bid/ask volumes on OTC are not in hundreds like on exchanges.
Here’s a few solid ideas to start (not in prioritized order):
- Work with the management to decrease outstanding share count.
- Continue to increase profitability (potentially current strategic state)
- Complete separation from Elite and CEO’s company, Mikah
- Separate CEO & Chairman roles
- Uplist off OTC
- Implement a small recurring buyback that swallows up more than the annual dilution (going back to first point)
- Get some of those big needle movers filed so investors can see the BE study results, products and total market so actual analysis can be done on the pipeline.
- Hire a CFO that sticks around longer than a year.
- Submit financials without need for amendments.
- Build credibility with shareholders by doing what mgmt says company will do (much better than history, still long road ahead). A crushed stock from credibility being hammered is incredibly hard to fix. Financial results will speak for themselves when Elite gets larger products filed, approved & launched. It’s unlikely this will take place in 2024 so you’re looking 2-3 years out due to no big BE studies reported on yet and the time it takes from BE to FDA filing, approval (no CRLs despite Elite having a history of them) and launch.
“I invented the internet.”
- Abraham Lincoln
CEO & chairman need to be separate roles. Otherwise there is no accountability.
Someone is always getting their bottom hammered. It’s just usually ELTP shareholders. Perhaps that what is meant by the poster.
Sort of choppy, but from the transcript:
“And we launched as April 1st, slow and study and May was much better than April and June was better than April and May. And July will be that and August will part to tip-off and after that we will be in a nice trajectory.”
Good post. Last cc Nasrat stated that August is the tipping point for the future trajectory.
Assuming we still have the Q2 conf call in 2 weeks we’ll get a better glimpse at July and August MTD in the commentary.
Piss poor interpretation, as usual. Just not expecting massive volume from Adderall because no realistic signs point to it how the FDA actually works.
The ELTP King of the Clowns doesn’t get the relationship between big pharma and the FDA. Who pays the fees to keep the FDA running? You think they are going to bite the hand that feeds them? I’m really sorry if you believe that.
Yes, love how you twist words as usual, but to be expected from a 3rd grader.
Clearly to provide truth and reality to the garbage you post day in day out.
I would be shocked if they don’t have a bad wrap in the area with all the crazy CFO turnover. On Glassdoor 64% of reviews recommend the company to a friend and the approve of the CEO.
On the flip side, it’s a small company that has very few reviews.
You are implying that all any beneficial unused allotment will go to Elite. Your assumption is far fetched at very best. Come back to reality. Elite has consistently struggled getting API. They might get a little more, but nothing material.
Lol, we’ll see. This is suggesting Elite is the only manufacturer. Get real and wake up.
2 & 3 are tiny drugs. Dexcel may not amount to anything. Vigabatrin is only a 3-year contract and we’re what half-way through the agreement with no launch? Generic oxy will not launch next year even if approved. $70M has no realistic basis whatsoever. Any increase in Adderall will be minimal, but the price of Mikah’s 50% will go up much more. Love how he plays both sides.
Maybe by next year…
Lannett barely scratched the surface with ER potential. Doing 1.5x this is still pitiful, but it’s out of Elite’s hands.
So what? And now the FDA is calling for urgency so these companies sharpen their focus on Adderall. They aren’t simply going to give up their allotment. They will stall or do whatever they can to prevent lost business moving to competitors.
That doesn’t mean anything for Elite. It might simply mean those not producing much actually start moving on it. Your $70M from Adderall is completely and entirely unreal for 2024.
Probably hammer bottom 5 of 1,500
Urging, but not permitting more API?
TOS policy changes turned this into a cesspool POS
Mute button makes a world of difference. Actually worked this time for me.
No investors like filing delays. If you do, you would be the first.
If they file on time. I’m hoping they are using a 3rd party to manage finance/accounting while they search for a new CFO. Otherwise, financial release will be delayed.
Nice article, thanks for sharing.
I worked for a major pharma & insurance company and they bought inventory in advance of need to avoid anticipated inflation. It was a cost avoidance play. I’m curious if all pharma do this for the same reason. Prices almost always go up, so if you buy in advance there are real savings.
I think that’s all great in theory, but why would a company want to give up any of their allotment to a competitor?
My apologies. I am going to put him on ignore.
You haven’t been able to post one lie and yet you repeat it over and over. I don’t lie. You just can’t understand how the OTC works and you are pissed. You should probably stick with a high yield savings account.
I provide balance. I oppose the constant hyping that this board has done for years. Where there is crap I call it out with truth. You just don’t realize or understand it yet.
Yes, read the 10K and be sure to understand the CEO’s ownership of Mikah and the non-arms relationship. Check out the ages of the BOD too. Be sure to investigate why this company has gone through 4 CFOs in quick succession.
Ignoring feature works less than half the time.
Why do you think I’m all over your posts? You either know you are posting garbage or are that clueless. I’m not sure which.
You are the one saying I don’t own stock. Your cyber skills need a reality check. Where I see lies, I am here to correct. It’s as simple as that.
I await with bated breath to show how wrong you are. Keep getting pulled into the fictional story though. That’s how Jan 6th events came about.
Wow, that is the most fictitious story I have ever heard. Lol
Can’t wait to see what’s in chapter two? May want to change your name. Your sleuthing skills really, really suck.
Are you sure? If so, you’ve joined the clueless club.
You didn’t even read the entire post. You simply don’t understand how the OTC works.
I see your point, but don’t forget the following:
- We are on the OTC.
- No investment funds can buy this stock.
- There is a long history of failure no ROI for shareholders with this company.
- As investors place trust in management, the share price is compensated believing that the strategic plans will be executed. Trust is harder to rebuild than doing what you say you will and don’t, time and time again. It’s much, much harder to rebuild credibility. This is Elite’s situation.
- How much will CEO milk Elite for Mikah? Until Mikah and Elite fully separate, this relationship will be a Bain for shareholders. The CEO is blind to this fact.
- CFO leaving is a bigger red flag than when a CEO leaves. When 3 CFOs leave in quick succession, you’re in uncharted waters weighing down on the stock. Knowing the past, shareholders are waiting for another shoe to drop because it often does.
- Retail shareholders don’t have the financial firepower to lift this company out of the cellar.
- Management ignores retail shareholders because they provide no value to the company. Sad, but it’s the reality. No IR likes dealing with the retail side and are more often than not, ignored. If you own 10%, now you might have a seat at the table.
These are just a handful of factors of why the stock price is where it is. Simply don’t ignore the risks.
On the flip side, when will we hit the point where the future potential outweighs those risks. That’s the discussion to be had.